Last updated: May 30, 2026
Macrobid is a brand of nitrofurantoin monohydrate/macrocrystals (a fixed-dose oral antibacterial). The supplier landscape is split into (1) nitrofurantoin API (and related intermediate) supply, (2) finished-dose manufacturer/labeler sources for the drug product, and (3) packaging and distribution logistics. Under US FDA oversight, the practical “supplier” set that matters for market entry and procurement is the finished-dose holders and the contract manufacturing and packaging networks supporting NDA/ANDA supply.
What companies supply nitrofurantoin API used to make Macrobid?
Nitrofurantoin API supply is concentrated among global chemical manufacturers that produce nitrofurantoin and then support formulation makers through qualified supply chains. For Macrobid specifically, the brand’s finished-dose product is produced by or for its NDA holder/labeler; upstream API qualification is typically vendor- and site-specific and is reflected in current good manufacturing practice (cGMP) supply networks and FDA inspections rather than public “buyer lists.”
Procurement implication: For R&D, licensing, or generic entry risk mapping, API suppliers should be validated via finished-dose manufacturer qualification records, DMF linkage, and FDA facility inspection history tied to nitrofurantoin API and finished-dose sites.
How to identify nitrofurantoin API suppliers tied to Macrobid manufacturing sites
The most direct way to map “API suppliers” to “who actually makes what for Macrobid” is to use:
- FDA’s Orange Book listing tied to Macrobid and the associated labeler/manufacturer entries.
- FDA facility and inspection data for nitrofurantoin API producers and the finished-dose plants manufacturing nitrofurantoin monohydrate/macrocrystals.
- DMF references in relevant ANDAs or permitted drug applications (when publicly visible through application disclosures or later filings).
Who manufactures the finished-dose Macrobid capsules and who packages them?
For market access, finished-dose capsule manufacturing and packaging are the operational suppliers. These are the firms whose plants make the nitrofurantoin monohydrate/macrocrystals capsules (typically hard gelatin capsules filled with a blend of the monohydrate and macrocrystal components) and perform packaging, labeling, and distribution.
Procurement implication: If you are evaluating supply stability, contract manufacturing capacity, or generic transfer risk, focus on:
- The FDA-identified manufacturing site(s) for the capsule dosage form.
- The packaging and labeling steps and their associated facilities (often different from the drug-product manufacturing site).
What is the Orange Book status of Macrobid and which labelers are listed?
Macrobid’s regulatory status determines which entities can be expected to have the branded supply network and which later ANDA sponsors may have entered. Orange Book listings also provide the basis for mapping patent-protected formulations and potential authorized generics.
Procurement implication: Orange Book entries provide the most defensible public starting point for “who is selling the product under the NDA” and can be cross-walked to manufacturing site information.
Which generic or authorized generic entrants compete with Macrobid supply?
Competition affects supply reliability and the distribution footprint of nitrofurantoin products. Generic entry also changes procurement options for wholesalers and specialty distributors, and it alters the set of contract manufacturers willing to produce the same dosage form.
Procurement implication: When supply is constrained (a recurring pattern in many older antibiotics), generic and authorized generic production can partially stabilize the market but also concentrates capacity at a smaller number of manufacturers.
What are the main contract manufacturing and packaging barriers for nitrofurantoin capsules?
Manufacturing barriers are driven by the drug’s combination composition, particle size control, blend uniformity, and encapsulation performance.
Key operational risk points:
- Consistent monohydrate-to-macrocrystal ratio and particle characteristics
- Controlled moisture sensitivity and stability
- Capsule filling reproducibility and dissolution profile control
- Regulatory-compliant quality systems and validated dissolution specifications
- Equipment clean-out verification to avoid cross-contamination with other antibiotics
Timeline: when do supplier bottlenecks typically emerge for Macrobid?
For older oral antibiotics with stable demand, supply disruptions typically emerge from:
- API supply constraints (chemical plant shutdowns, yield loss, export restrictions)
- Limited capacity in qualified encapsulation lines
- Recalls or quality events requiring site remediation
- Transportation and packaging material constraints (gelatin capsule supply, labeling substrates)
Procurement implication: Monitoring FDA drug shortages and market withdrawal notices is central for identifying when supply shifts from one manufacturer to another.
How does Macrobid compare with nitrofurantoin alternatives that change supplier options?
In the US, the competitive set includes:
- Other nitrofurantoin dosage forms (for example, macrocrystalline and monohydrate combinations in capsule form, and other nitrofurantoin product presentations where marketed)
- Different brands of nitrofurantoin products with different strengths, release characteristics, and manufacturing networks
Procurement implication: If Macrobid is constrained, substitution options depend on formulary equivalence, labeling, and pharmacy substitution rules. Supplier mapping should account for these alternates because they often have different manufacturing sites.
What does supplier due diligence require for Macrobid procurement or licensing?
For high-stakes R&D or licensing decisions, supplier diligence should verify:
- Site qualification for capsule filling and dissolution testing capability
- Proven batch-to-batch consistency for monohydrate/macrocrystal blend
- Documented stability data for the exact packaging configuration
- Ability to supply the full commercial pack configuration (bottles/cartons, NDC-specific label formats)
How to build a practical Macrobid supplier map (API to finished-dose)
A defensible supplier map is built using a chain-of-evidence:
- Identify the NDA labeler(s) and the drug-product manufacturing site(s) from FDA listing data.
- Tie the finished-dose sites to their upstream inputs by linking inspection records and, where visible, DMF references.
- Validate packaging facilities based on the packaging and labeling entries on FDA listing data and site inspection scope.
- Overlay drug shortage and discontinuation events to understand which sites are stressed.
Key Takeaways
- “Suppliers for Macrobid” should be treated as a network: nitrofurantoin API producers feeding qualified capsule drug-product manufacturing sites, with separate packaging and labeling suppliers that control final market availability.
- The most defensible public starting point for mapping suppliers is FDA listing data tied to Macrobid’s labeler/manufacturer and the capsule dosage form; those entries can be cross-checked to identify the cGMP sites that matter for procurement and market entry.
- Supplier bottlenecks are typically driven by API constraints, encapsulation capacity, and quality events at specific qualified sites, so due diligence must anchor on manufacturing and packaging facilities, not just brand marketing names.
FAQs
- What does the FDA Orange Book show for Macrobid labeler and manufacturer entries?
- Which manufacturing sites are most likely responsible for nitrofurantoin monohydrate/macrocrystals capsule supply continuity?
- How do DMFs and site inspections help identify upstream nitrofurantoin API suppliers linked to Macrobid production?
- What packaging components (capsules, bottle closures, labeling substrates) most commonly disrupt Macrobid supply?
- How do nitrofurantoin product alternates change procurement options when Macrobid has shortage pressures?
References (APA)
- U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/
- U.S. Food and Drug Administration. Drug Shortages. https://www.accessdata.fda.gov/scripts/drugshortages/
